<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03068364</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL17_0151</org_study_id>
    <nct_id>NCT03068364</nct_id>
  </id_info>
  <brief_title>Biological and Electrocardiographic Biomarkers for Risk Stratification in Hypertension.</brief_title>
  <official_title>Additive Value of Biological and Electrocardiographic Biomarkers for Risk Stratification in Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Risk stratification of hypertensive patients includes assessment of traditional&#xD;
      cardiovascular risk factors and subclinical target organ damages particularly left&#xD;
      ventricular hypertrophy (LVH).&#xD;
&#xD;
      LVH may routinely screened by transthoracic echocardiography by measuring the left&#xD;
      ventricular mass (LVM).&#xD;
&#xD;
      However, transthoracic echocardiography suffers from several pitfalls: poor reproducibility,&#xD;
      technical limitations and unavailability at a first evaluation by general practitioners.&#xD;
&#xD;
      Other biomarkers may be particularly helpful in hypertension risk stratification. The&#xD;
      amplitude of the R wave in aVL lead is a simple validated ECG parameters of LVH and a strong&#xD;
      predictor of cardiovascular events and mortality.&#xD;
&#xD;
      Plasma N-terminal pro Brain Natriuretic Peptide (NT-proBNP) is also strongly related to LVM&#xD;
      and is an independent predictor of all-cause mortality in hypertension.&#xD;
&#xD;
      The main objective of our study is to determine the additive prognostic value of R wave in&#xD;
      aVL and NT proBNP on all-cause and cardiovascular mortality.&#xD;
&#xD;
      Secondary objectives are to determine the addition prognostic value of NT-proBNP and R wave&#xD;
      in aVL combined in comparison to each marker taken into account&#xD;
&#xD;
      This study will include 1600 patients who had a work-up of their hypertension in the&#xD;
      Cardiology Department of Croix-Rousse Hospital (Hospices Civils de Lyon, Lyon, France) from&#xD;
      January 1997 to January 2014.&#xD;
&#xD;
      Their data will be collected in an Access database; their vital status will be obtained by&#xD;
      the INSEE unit CépiDC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 3, 2016</start_date>
  <completion_date type="Actual">February 17, 2017</completion_date>
  <primary_completion_date type="Actual">February 17, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All- cause and cardiovascular mortality in hypertension</measure>
    <time_frame>an average of 7 years</time_frame>
    <description>All-Cause and cardiovascular mortality will be obtained from the INSERM unit CépiDC.&#xD;
Vital status was obtained in July 2016</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause and cardiovascular deaths</measure>
    <time_frame>an average of 7 years</time_frame>
    <description>All-cause and cardiovascular deaths in the study population will be obtained from the INSERM unit CépiDC.&#xD;
Vital status was obtained in July 2016</description>
  </secondary_outcome>
  <enrollment type="Actual">1600</enrollment>
  <condition>Hypertension</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients, who had a work-up of their hypertension in the Cardiology Department of&#xD;
        Croix-Rousse Hospital (Hospices Civils de Lyon, Lyon, France) from January 1997 to January&#xD;
        2014.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  Inclusion Criteria:&#xD;
&#xD;
               -  &gt;18 years old&#xD;
&#xD;
               -  men or women&#xD;
&#xD;
               -  questionnaire completion and physical exam during their first stay in the&#xD;
                  Cardiology Department of from January 1997 to January 2014.&#xD;
&#xD;
          -  Exclusion Criteria:&#xD;
&#xD;
               -  Patients refusal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Pierre LANTELME</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Hopital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>February 27, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mortality</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Left ventricular hypertrophy</keyword>
  <keyword>NT-proBNP</keyword>
  <keyword>ECG</keyword>
  <keyword>Transthoracic echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

